Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $10.42 million. The enterprise value is $7.69 million.
Important Dates
The last earnings date was Thursday, November 21, 2024, before market open.
Earnings Date | Nov 21, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Evogene has 6.79 million shares outstanding. The number of shares has increased by 21.07% in one year.
Current Share Class | 6.79M |
Shares Outstanding | 6.79M |
Shares Change (YoY) | +21.07% |
Shares Change (QoQ) | +14.07% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 6.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 0.88 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.03 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.06.
Current Ratio | 1.09 |
Quick Ratio | 1.03 |
Debt / Equity | 0.06 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -10.24 |
Financial Efficiency
Return on equity (ROE) is -105.55% and return on invested capital (ROIC) is -61.89%.
Return on Equity (ROE) | -105.55% |
Return on Assets (ROA) | -31.64% |
Return on Capital (ROIC) | -61.89% |
Revenue Per Employee | $52,662 |
Profits Per Employee | -$165,585 |
Employee Count | 142 |
Asset Turnover | 0.15 |
Inventory Turnover | 2.96 |
Taxes
Income Tax | -2,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.14% in the last 52 weeks. The beta is 1.08, so Evogene's price volatility has been similar to the market average.
Beta (5Y) | 1.08 |
52-Week Price Change | -81.14% |
50-Day Moving Average | 1.80 |
200-Day Moving Average | 4.62 |
Relative Strength Index (RSI) | 55.34 |
Average Volume (20 Days) | 64,201 |
Short Selling Information
Short Interest | 38,104 |
Short Previous Month | 81,969 |
Short % of Shares Out | 0.42% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, Evogene had revenue of $7.48 million and -$23.51 million in losses. Loss per share was -$4.48.
Revenue | 7.48M |
Gross Profit | 5.15M |
Operating Income | -24.77M |
Pretax Income | -21.46M |
Net Income | -23.51M |
EBITDA | -23.00M |
EBIT | -24.77M |
Loss Per Share | -$4.48 |
Full Income Statement Balance Sheet
The company has $19.95 million in cash and $686,000 in debt, giving a net cash position of $19.27 million or $2.84 per share.
Cash & Cash Equivalents | 19.95M |
Total Debt | 686,000 |
Net Cash | 19.27M |
Net Cash Per Share | $2.84 |
Equity (Book Value) | 12.24M |
Book Value Per Share | -0.64 |
Working Capital | 2.07M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$20.42 million and capital expenditures -$390,000, giving a free cash flow of -$20.81 million.
Operating Cash Flow | -20.42M |
Capital Expenditures | -390,000 |
Free Cash Flow | -20.81M |
FCF Per Share | -$3.06 |
Full Cash Flow Statement Margins
Gross Margin | 68.90% |
Operating Margin | -331.25% |
Pretax Margin | -339.50% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -21.07% |
Shareholder Yield | -21.07% |
Earnings Yield | -225.60% |
FCF Yield | -199.65% |
Analyst Forecast
The average price target for Evogene is $12.00, which is 627.27% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12.00 |
Price Target Difference | 627.27% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 0.1:1.
Last Split Date | Jul 25, 2024 |
Split Type | Reverse |
Split Ratio | 0.1:1 |
Scores
Evogene has an Altman Z-Score of -10.66 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -10.66 |
Piotroski F-Score | 2 |